Efficient repositioning of approved drugs as anti-HIV agents using

Anti-HIV-Predictor

Shao-Xing Dai^{1,3,#,*}, Huan Chen^{2,3,#}, Wen-Xing Li^{1,4,#}, Yi-Cheng Guo¹, Jia-Qian Liu^{1,3}, Jun-Juan Zheng^{1,3}, Qian Wang^{1,3}, Hui-Juan Li^{1,3}, Bi-Wen Chen¹, Yue-Dong Gao⁵, Gong-Hua Li^{1,3,*}, Yong-Tang Zheng^{2,3,6,7,8,*} and Jing-Fei Huang^{1,3,6,7,8,*}

¹ State Key Laboratory of Genetic Resources and Evolution, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, Yunnan, China

² Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences and Yunnan Province, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, Yunnan, China

³ Kunming College of Life Science, University of Chinese Academy of Sciences, Beijing 100049, China

⁴ Institute of Health Sciences, Anhui University, Hefei 230601, Anhui, China

⁵ Kunming Biological Diversity Regional Center of Instruments, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, China

⁶ KIZ-SU Joint Laboratory of Animal Models and Drug Development, College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China

⁷ Collaborative Innovation Center for Natural Products and Biological Drugs of Yunnan, Kunming 650223, Yunnan, China

⁸ KIZ/CUHK Joint Research Center for Bio-resources and Human Disease Mechanisms, Kunming 650223, China

These authors contributed equally to this work.

* Corresponding author:

Shao-Xing Dai (daishaoxing@mail.kiz.ac.cn)

Gong-Hua Li (ligonghua@mail.kiz.ac.cn)

Yong-Tang Zheng (zhengyt@mail.kiz.ac.cn)

Jing-Fei Huang (huangjf@mail.kiz.ac.cn)

Tel: +86 0871 65195400

Fax: +86 0871 65195400

Abstract

Development of new, effective and affordable drugs against HIV is urgently needed. In this study, we developed a world's first web server called Anti-HIV-Predictor (<http://bsb.kiz.ac.cn:70/hivpre>) for predicting anti-HIV activity of given compounds. This server is rapid and accurate (accuracy >93% and AUC > 0.958). We applied the server to screen 1835 approved drugs for anti-HIV therapy. Totally 67 drugs were predicted to have anti-HIV activity, 25 of which are anti-HIV drugs. Then we experimentally evaluated 35 predicted new anti-HIV compounds by assays of syncytia formation, p24 quantification, cytotoxicity. Finally, we repurposed 7 approved drugs (cetorelix, dalbavancin, daunorubicin, doxorubicin, epirubicin, idarubicin and valrubicin) as new anti-HIV agents. The original indication of these drugs is involved in a variety of diseases such as female infertility and cancer. Anti-HIV-Predictor and the 7 repurposed anti-HIV agents provided here demonstrate the efficacy of this strategy for discovery of new anti-HIV agents.

Introduction

Even 30 years after its discovery, human immunodeficiency virus (HIV) remains a great threat to humans^{1,2}. Acquired immune deficiency syndrome(AIDS), the disease elicited by HIV infection, is considered to be pandemic and represents the greatest global public health crisis³. There are an estimated 39 million deaths caused by AIDS since its first recognition⁴. According to the report of the World Health Organization(WHO), there were approximately 37 million people living with HIV at the end of 2014 with 2 million people becoming newly infected with HIV in 2014 globally. And 1.2 million people died from HIV-related causes globally in 2014 (<http://www.who.int/mediacentre/factsheets/fs360/en/>).

Many scientists around the world are committed to finding scientifically proven strategies for HIV prevention and treatment. Recent decades, significant progress has been achieved in the development of vaccines and drugs against HIV infection. Several clinical trials of anti-HIV vaccines, including RV144, are ongoing^{5,6}. The RV144 trial demonstrated 31% vaccine efficacy at preventing human immunodeficiency virus (HIV)-1 (referred to as HIV for the rest of this study) infection⁷. The most notable achievement is the transformation of HIV/AIDS from an inevitable death sentence to a chronic illness by the introduction of combination antiretroviral therapy^{8,9}. More than thirty anti-HIV drugs have been approved by the US Food and Drug Administration (FDA)¹⁰. These drugs act mainly on reverse transcriptase, protease, integrase, CCR5 and so on¹¹. Behind the progress, many studies were carried out to discover anti-HIV drug candidates by screening a large number of natural or synthetic compounds. A representative study was the AIDS anti-viral screen program of the National Cancer Institute (NCI), which screened more than 30,000 compounds (<https://dtp.cancer.gov/>)^{12,13}. After this program, many anti-HIV compounds were reported and deposited in ChEMBL database (ChEMBLdb)¹⁴. These data are helpful for data mining and developing new tool toward HIV treatment.

Despite considerable progress, treatment of AIDS still faces multiple challenges^{15,16}. To date, no truly effective drug able to eliminate HIV has been developed¹⁷. Furthermore, HIV is highly variable and can quickly acquire resistance against any drug with which it is confronted^{11,18}. Therefore, there is a constant demand to develop new, effective and affordable anti-HIV drugs. In the past decades, tens of millions of chemical compounds have been deposited in public databases¹⁹. Screening these huge databases for new anti-HIV drugs through experimental methods is a tedious, expensive and time-consuming process. The time and money-saving way is that all compounds in the database are

firstly filtered by the computational analysis of the anti-HIV potential, then evaluated by experiment. Therefore, a rapid and accurate computational method is urgently required for predicting anti-HIV activity of chemical compounds.

In this study, we aim to establish a web server to predict anti-HIV activity of given compound and apply the web server to discover new anti-HIV agents through drug repositioning of FDA approved drugs (**Figure 1**). Drug repositioning is the process of finding new uses outside the scope of the original medical indication for existing drugs^{20,21}. An advantage of drug repositioning lies in the fact that the safety, dosage, and toxicity of existing drugs have already been vetted²². Therefore, repurposed candidate drugs can often enter clinical trials much more rapidly than newly developed drugs²³. Recently, many anti-infectious agents have been discovered to combat pathogens using drug repositioning²⁴⁻²⁸.

Therefore, in this study, we firstly developed three rapid and accurate computational methods to predict anti-HIV activity of a given compound. Then a web server called Anti-HIV-Predictor (<http://bsb.kiz.ac.cn:70/hivpre>) is established by integrating the three methods. This web server is free and open to all users. All FDA approved drugs were screened using the web server. Finally, the predicted new anti-HIV compounds were selected for *in vitro* testing of anti-HIV activity. Using this strategy, we identified cetrorelix, dalbavancin and five anthracycline drugs as new potent anti-HIV agents.

Results

Development of Anti-HIV-Predictor

Workflow for establishing Anti-HIV-Predictor is outlined in **Figure 1**. Anti-HIV-Predictor firstly integrated all the data of anti-HIV activity from ChEMBL and NCI database to construct benchmark dataset. Then, using the benchmark dataset, three prediction models were generated by training, parameter selection and validation. The first model is relative frequency-weighted fingerprint (RFW_FP) based model. RFW_FP is a novel molecular description method which considers the frequency of bit in active and inactive datasets and integrates it to each compound fingerprint. RFW_FP was first used in our previous study and powerful to distinguish the active and inactive compounds for anti-cancer^{29,30}. The other two models are Support Vector Machine (SVM) and Random Forest (RF) models. Last, three models (RFW_FP model, SVM model and RF model) were incorporated to predict anti-HIV activity of chemical compounds. The details for development of

Anti-HIV-Predictor are given in the **Materials and methods** section.

Performance of Anti-HIV-Predictor

The overall performance of the RFW_FP, SVM and RF models was quantified by receiver operating characteristic curve (ROC). For each model, the ROC was plotted and the area under the curve (AUC) was calculated (**Figure 2a**). The ROC curve shows the relation between true positive rate and false positive rate for each threshold of the real-value outputs. The AUC value of the RFW_FP, SVM and RF models are 0.958, 0.974 and 0.977, respectively. All three models achieve AUC value greater than 0.958, which reveals the excellent effectiveness of the models. From the three curves, we can also observe that the three models can effectively identify active anti-HIV compounds with high true-positive rates against low false positive rates.

The classification performance of the models was also assessed in terms of accuracy, precision, recall and F1 score (**Figure 2b**). As 10 runs of 5-fold cross-validation (CV) method were used, these scores were averaged. Over the ten runs, their standard deviations were also reported. As shown in **Figure 2b**, the RFW_FP model obtains the statistical average of 93.3%, 86.9%, 90.1%, and 88.5% for accuracy, precision, recall, and F1 score, respectively. The accuracy, precision, recall, and F1 score of SVM model are 96%, 95%, 90.8%, and 92.9%, respectively. RF model performs best with the accuracy of 96% and precision of 99.4%.

Input and output of Anti-HIV-Predictor

Anti-HIV-Predictor is user-friendly and free and open to all users. The only requirement of Anti-HIV-Predictor is the SMILES of the query compound. One or multiple query compounds can be submitted in one request (**Figure 2c**). The total number of input compounds is limited to 100 for each submission. Anti-HIV-Predictor needs about 60 seconds to load the background data and trained models required for prediction. Therefore, 1-10 compounds requires about 90 seconds, but 100 compounds only requires about 150 seconds. A query with 1–10 compounds requires about 90 seconds, whereas a query with 100 compounds only requires about 150 seconds. After calculated, the output of Anti-HIV-Predictor was shown in **Figure 2d**. Firstly, the output gives the most similar compound of the query compound. The structures, database links and anti-HIV activities ($\log EC_{50}$) of the matched similar compound were also displayed. Secondly, the output contains some important predicting information, for example, Tanimoto Coefficient score (TC), the Relative Frequency-Weighted Tanimoto Coefficient (RFW_TC), P-value of RFW_TC model, probability estimation by SVM model

and RF model. Finally, the output shows the predicting conclusion whether the query compound has anti-HIV activity. One tick represents the query compound is predicted as anti-HIV compound by one of the three models. One cross means that all the three models show no anti-HIV activity for the query compound.

Rapid and accurate computational screen of FDA approved drugs using Anti-HIV-Predictor

To discover new anti-HIV agents through drug repositioning of FDA approved drugs, 1835 approved drugs with SMILES string were downloaded from DrugBank (<http://www.drugbank.ca>). Using Anti-HIV-Predictor, all the drugs were screened rapidly by the three models. The results of computational screen are shown in **Figure 3**. Most drugs have no anti-HIV activity based on the prediction. These drugs were shown as blue dots with RFW_TC P-value ≥ 0.05 , SVM probability and RF probability ≤ 0.5 (**Figure 3a**). The green dots represent the drugs with anti-HIV activity supported by one or two models (RFW_TC P-value < 0.05 or SVM probability > 0.5 or RF probability > 0.5). The red dots represent the drugs with anti-HIV activity supported by all three models (RFW_TC P-value < 0.05 and SVM probability > 0.5 and RF probability > 0.5). As shown in **Figure 3b**, totally 67 drugs were predicted to have anti-HIV activity by all three models. The RFW_FP, SVM and RF models predicted 240, 178, 110 drugs with anti-HIV activity, respectively. Therefore, the 67 drugs represent the intersection of the results of the three different models (**Figure 3b**). Among the 67 drugs, there are 25 approved anti-HIV drugs and 7 drugs with anti-HIV activity. For other 35 drugs, there is no experimental test for anti-HIV activity (**Table S1**).

Experimental confirmation of 15 approved drugs with anti-HIV activity

As the 35 drugs have not been experimental test for anti-HIV activity, it is interesting and worth evaluating their anti-HIV activity by experiment. 28 of these drugs were purchased from CASMART (<http://www.casmart.com.cn>). Other 7 drugs are not purchased and tested because they are not available or very expensive. Therefore, a total of 28 drugs were evaluated for their anti-HIV activity *in vitro* with azidothymidine (AZT) as a positive control. The cytotoxicity of these compounds on T cell line C8166 was assessed by MTT colorimetric assay, and 50% cytotoxicity concentration (CC_{50}) was calculated. The inhibitory effect of compounds on HIV replication was measured by the syncytia formation assay and 50% effective concentration (EC_{50}) was calculated as described previously. The

assay results of the 28 compounds are presented in **Table 1**. For comparison, AZT, the first anti-HIV drug approved by FDA, was utilized as the reference compound. As shown in **Table 1**, 15 compounds show anti-HIV activity with the EC₅₀ values ranging from 0.004 to 93.794 μ M. More than half of the tested compounds (15/28) exhibit activity against HIV. It indicates that Anti-HIV-Predictor is a powerful tool for discovering anti-HIV compounds.

Identification of 7 approved drugs as new anti-HIV agents

Among the 15 compounds above, some compounds show serious cytotoxicity and then result in a very low therapeutic index (TI). The drugs with TI value more than 10 were further evaluated their anti-HIV activity by quantification of HIV p24 expression using ELISA method³¹. The best 7 drugs based on the results of cytotoxicity, syncytia formation and p24 quantification assays were displayed in **Table 2** and **Figure 4**. Among the best 7 drugs, cetrorelix and dalbavancin are polypeptides, while other five drugs daunorubicin, doxorubicin, epirubicin, idarubicin and valrubicin belong to the class of anthracyclines. Cetrorelix, a synthetic decapeptide, is used for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian stimulation³². Dalbavancin, a second-generation lipoglycopeptide antibiotic, is approved for the treatment of acute bacterial skin and skin structure infections caused by the gram-positive pathogens³³. Cetrorelix and dalbavancin exhibit anti-HIV activity with EC₅₀ of 1.788 $\pm$ 0.115 and 1.296 $\pm$ 0.186 μ M, respectively. No cytotoxicity was detected for cetrorelix and dalbavancin. The cytotoxicity CC₅₀ of cetrorelix and dalbavancin are both more than 200 μ M. The percent viability at the concentration EC₅₀ is almost 100% for cetrorelix and dalbavancin (**Figure 4**). Therefore, cetrorelix and dalbavancin show a very high therapeutic index (TI>105 and TI >135, respectively). The five anthracycline drugs are approved for the treatment of acute myeloid leukemia, bladder and breast cancer and so on³⁴. These anthracycline drugs show strong anti-HIV activity with EC₅₀ varying from 0.003~0.076 μ M. The anti-HIV activity of Idarubicin is close to or better than that of AZT (0.003 μ M for Idarubicin vs 0.005 μ M for AZT). However, these anthracycline drugs exhibit a certain degree of cytotoxicity (**Figure 4**). The percent viability at the concentration EC₅₀ is ranging from 80% to 95% for the five drugs. It indicates that, the anti-HIV activity mainly results from the selective inhibition of HIV replication and less due to toxicity. Their therapeutic index is ranging from 5.9 to 64.8 and far below that of AZT.

Discussion

The failure of 30 years of HIV vaccine development^{5,35}, as well as the prevalence of drug-resistant

HIV³⁶⁻³⁸, emphasizes the need for new, effective and affordable anti-HIV drugs. To decrease the cost and time required for the development of new drugs to treat HIV infection, a world's first web server Anti-HIV-Predictor was developed for predicting anti-HIV activity of compounds. The accuracy of the web server is more than 93% and AUC is greater than 0.958, which indicates that Anti-HIV-Predictor is powerful enough to discover new anti-HIV agents. Using Anti-HIV-Predictor, 1835 approved drugs were computational screened rapidly. A total of 67 drugs were predicted as anti-HIV compounds. Almost half of the 67 drugs are approved for anti-HIV therapy or with anti-HIV activity. Among the 67 drugs, the drugs with no experimental data for anti-HIV activity were experimentally evaluated in this study. Based on the results of cytotoxicity, syncytia formation and p24 quantification assays, 7 approved drugs (cetorelix, dalbavancin, daunorubicin, doxorubicin, epirubicin, idarubicin and valrubicin) were identified as new potential anti-HIV agents.

Screening 1835 approved drugs for new anti-HIV drugs through experimental methods is a tedious, expensive and time-consuming process. In this study, the 7 new compounds were rapidly repurposed for anti-HIV therapy from the huge approved drugs library. This process of drug repositioning, which is time and money saved, has benefited from the web server Anti-HIV-Predictor. In silico screen of the approved drugs library using Anti-HIV-Predictor only needs less than one hour. After screening, the predicted anti-HIV compounds can be experimentally evaluated immediately. The rapidity and accuracy of Anti-HIV-Predictor make it powerful for discovery of new anti-HIV agents. In future, we will use Anti-HIV-Predictor to screen other compound database such as TCM Database@Taiwan³⁹ and Human Metabolome Database^{40,41} for discovery of new natural product against HIV.

Cetorelix, a synthetic decapeptide, is used in assisted reproduction to inhibit premature LH surges. The drug works by blocking the action of gonadotropin-releasing hormone (GnRH) upon the pituitary, thus rapidly suppressing the production and action of LH and follicle-stimulating hormone (FSH)³². It is administered as 0.25 mg or 3 mg for one subcutaneous injection. The administered dosage is equal to 0.034 - 0.402 μ M (0.25 - 3 mg/5L blood) in human blood which is close to the concentration EC₅₀ (1.788 μ M) for anti-HIV activity. Therefore, administration of cetorelix as the same for original indication of assisted reproduction may have clinical benefit to HIV-infected patients. Dalbavancin is a novel second-generation lipoglycopeptide antibiotic. It possesses *in vitro* activity against a variety of gram-positive pathogens. Dalbavancin exerts its bactericidal effect by disrupting cell wall

biosynthesis³³. It is administered as 500 mg for one subcutaneous injection. The administered dosage is equal to 55.03 μM (500 mg/5L blood) in human blood which is far higher than the concentration EC_{50} (1.296 μM) for anti-HIV activity. Therefore, administration of dalbavancin as the same for treatment of bacterial infection is very promising to have clinical benefit to HIV-infected patients.

The five anthracycline drugs daunorubicin, doxorubicin, epirubicin, idarubicin and valrubicin identified in this study have potent anti-HIV activity at the nanomolar level. Although they are more toxic than cetorelix and dalbavancin, their therapeutic index is all more than 10. The therapeutic index of valrubicin is 18.3-64.8, which is the highest among the five drugs. The EC_{50} of idarubicin is 0.003 μM ($\text{TI}=18.3\text{-}40.0$), which is best among the five drugs. Idarubicin inhibits HIV-1 replication at the lowest concentration among the five drugs and close to or better than the positive control drug AZT. The five anthracycline drugs are approved for the treatment of lymphomas, leukemias, Hodgkin's disease, bladder cancer and so on³⁴. The HIV-infected patients were more likely to suffer from anal cancer and Hodgkin's lymphoma^{42,43}. HIV-infected patients with cancer are less likely to receive treatment for some cancers than uninfected people, which may affect survival rate^{43,44}. HIV-infected cancer patients are more likely to die from cancer than uninfected cancer patients. Therefore, the five drugs may be applied to treatment of the HIV-infected patients with cancer. These patients may benefit from the five drugs.

Anti-HIV-Predictor predicts anti-HIV activity of compounds based on the benchmark dataset containing active and inactive compounds. The compound with potent anti-HIV activity but less cytotoxicity is expected in the development of anti-HIV drug. Since the cytotoxicity is not taken into account in the current study, some of predicted compounds exhibit high cytotoxicity as shown in **Table 1**. Therefore, Anti-HIV-Predictor is open to improvement. In future, we will consider the cytotoxicity as important factor in the prediction of anti-HIV activity by integrating the NCI-60 growth inhibition data from NCI Development Therapeutics Program (DTP) (<https://dtp.cancer.gov/>)⁴⁵. The predicted anti-HIV compounds in the first step will be filtered by cytotoxicity feature. Anti-HIV-Predictor with cytotoxicity filter may results in a compound with high anti-HIV activity but less cytotoxicity.

Treatment of AIDS still faces multiple challenges such as drug resistance and HIV eradication. Development of new, effective and affordable drugs against HIV is urgently needed. Here we firstly developed a world's first web server Anti-HIV-Predictor for predicting anti-HIV activity of compounds and then applied the server to drug repositioning for anti-HIV therapy. Finally, we repurposed 7

compounds as new anti-HIV agents. The web server and the 7 repurposed anti-HIV agents provided here have an immediate effect on the development of new anti-HIV therapeutics, and should significantly advance current anti-HIV research.

Materials and methods

Construction of benchmark dataset

Anti-HIV activity data were downloaded from ChEMBLdb and NCI. In ChEMBLdb, the compound whose target is "human immunodeficiency virus type 1" and with the activity better than 10 $\mu\text{mol/L}$ was considered as active compounds. In NCI, the compound with more than 2 replication experiments and with EC_{50} less than 10 $\mu\text{mol/L}$ was considered as active compounds. And the other compounds with EC_{50} more than 100 $\mu\text{mol/L}$ were consider as inactive compounds. Finally, all compounds in the two databases were integrated by removed the conflict and replicated compounds. This procedure yielded 9584 active and 23998 inactive compounds, respectively. The active and inactive datasets were used as benchmark datasets to generate models to predict anti-HIV activity of chemical compounds. The detailed method of constructing benchmark dataset can be found in **Part 1 of Supplemental material**.

RFW_FP model

Firstly, Relative Frequency-Weighted Fingerprint (RFW_FP) was used to calculate the compound fingerprints. RFW_FP was calculated as follows:

$$\text{RFW_FP}(i) = \text{Bit}(i) \times \left(\frac{F_{\text{active}}(i)}{F_{\text{inactive}}(i)} \right)^{\alpha} \quad (1)$$

where i represents i th Daylight fingerprint. In Daylight theory, each compound contains more than one and less than 1024 fingerprints. $\text{RFW_FP}(i)$ is i th relative frequency-weighted fingerprint. $\text{Bit}(i)$ is calculated by Pybel⁴⁶, a python wrapper of Openbabel⁴⁷. if the compound has i th fingerprint, $\text{Bit}(i) = 1$, else $\text{Bit}(i) = 0$. $F_{\text{active}}(i)$ and $F_{\text{inactive}}(i)$ are the frequency of i th fingerprint in the active and inactive compounds, respectively. α is the amplifying factor. In this study, α was optimized as 0.5 (**Figure S2**).

Then, the Relative Frequency-Weighted Tanimoto Coefficient (RFW_TC) between two compounds was calculated as follows:

$$\text{RFW_TC}(m, n) = \frac{S_{mn}}{S_m + S_n + S_{mn}} \quad (2)$$

where $\text{RFW_TC}(m, n)$ is RFW_TC between two compounds m and n . S_m and S_n are the sum of RFW_FPs in compound m and n , respectively. S_{mn} is the sum of the common RFW_FPs between two

compounds.

Finally, for each query chemical compounds, the maximum RFW_TC between the query and the active dataset (9584 compounds) was calculated. Then the P-value, based on the maximum RFW_TC, was calculated. As the maximum RFW_TC is less than 1.0 and the maximum RFW_TCs of the inactive compounds have a normal distribution (**Figure S3**), we can calculate the P-value as follows:

$$p(\chi) = F(1.0; \mu, \sigma) - F(\chi; \mu, \sigma) \quad (3)$$

where $p(\chi)$ is the P-value at the maximum RFW_TC of χ ; $F(\chi; \mu, \sigma)$ is the cumulative function of normal distribution. Using the maximum likelihood method ("fitdist" function in R "fitdistrplus" package⁴⁸), we estimated the location parameter μ of 0.461, the scale parameter σ of 0.121.

SVM model

SVM is a powerful supervised learning algorithm suitable for non-linear classification problems⁴⁹. It is based on the idea of transforming data not linearly separable in feature space to a higher- or infinite-dimensional space where they can be separated linearly by a suitable soft-margin hyperplane⁵⁰. For our binary classification task, we firstly chosen kernel function and then perform a grid search of the penalty parameter C. The Scikit-learn Python wrappers for libsvm27 were used to choose kernel function and explore the hyper-parameter space^{51,52}. The best-performing model was selected by plotting receiver operating characteristic (ROC) curve and calculating the area under the curve (AUC). The model with kernel function rbf and the penalty parameter C of 500 performed best (**Figure S4**). The detailed method for the selection of kernel function and the penalty parameter C can be found in **Part 5 of Supplemental material**.

RF model

The algorithm of random forest is based on the ensemble of a large number of decision trees, where each tree gives a classification and the forest chooses the final classification having the most votes over all the trees in the forest⁵³. Random forest, implemented in Scikit-learn⁵¹, was chosen as classifier with the following settings: (1) Number of trees was set to 900 (`n_estimators = 900`). This parameter was selected by calculating AUC (**Figure S5**). (2) The minimum number of samples to split an internal node was set to 2 (`min_samples_split = 2`, default setting). (3) The minimum number of samples in newly created leaves was set to 1 (`min_samples_leaf = 1`, default setting). (4) The number of features to consider when looking for the best split was set to the square root of the number of descriptors (`max_features = auto`, default setting). (5) The maximum depth of the tree was expanded

until all leaves are pure or until leaves contain less than min_samples_split samples (max_depth = none, default setting). (6) Bootstrap samples were used (bootstrap = true, default setting). For further documentation on the random forest implementation in Scikit-learn, the interested reader is referred to the web site (<http://scikit-learn.org>).

Performance evaluation

To test performance of Anti-HIV-Predictor, 10 runs of 5-fold cross-validation (CV) method (**Part 2 of Supplemental material**) were used to the three models (RFW_FP model, SVM model and RF model). For each model, the ROC was plotted and the area under the curve (AUC) was calculated. The results of the CV tests were used to calculate the four quality indices: accuracy, precision, recall and F1 score which is defined as the harmonic mean of precision and recall. We used the default statistical definition for these quality indices:

$$\begin{aligned}\text{Accuracy} &= \frac{TP + TN}{TP + FP + TN + FN} \\ \text{Precision} &= \frac{TP}{TP + FP} \\ \text{Recall} &= \frac{TP}{TP + FN} \\ \text{F1 score} &= 2 \times \frac{\text{Precision} \times \text{Recall}}{\text{Precision} + \text{Recall}}\end{aligned}$$

where true positive (TP) and true negative (TN) correspond to correctly predicted anti-HIV compound and non anti-HIV, respectively, false positive (FP) denote non anti-HIV compound predicted as anti-HIV compound, and false negative (FN) denote anti-HIV compound predicted as non anti-HIV compound.

Compounds, cells and HIV-1 strain

The 28 approved drugs were purchased from CASMART (<http://www.casmart.com.cn>). C8166 and H9 cell was kindly provided by the AIDS Reagent Project, the UK Medical Research Council (MRC). Cells were maintained in RPMI 1640 medium (Life technology) containing 10% heat-inactivating fetal bovine serum (FBS, Life technology), 100units/mL penicillin (Sigma) and streptomycin (amresco). Laboratory adapted strain HIV-1_{NL4-3} was kindly donated by NIH and propagated in H9 cells. Virus stocks were stored in small aliquots at -70 °C.

Cytotoxicity assays

The cellular toxicity of tested compounds on C8166 was assessed by MTT colorimetric assay⁵⁴. Briefly,

4×10^4 per well C8166 cells were co-incubated with or without a series diluted test compounds. After 3 days of incubation at 37°C , 5% CO_2 , the cell viability was determined by using MTT. Afterward, the 50% cytotoxicity concentration (CC_{50}) was calculated. AZT was used as a positive control.

Inhibition of syncytia formation

The inhibitory effect of samples on acute HIV-1_{NL4-3} infection was measured by the syncytia formation assay as described previously⁵⁵. In the presence or absence of various concentrations of compounds, 4×10^5 /ml C8166 cells were infected with HIV-1_{NL4-3} at a multiplicity of infection (MOI) of 0.03, and cultured in 96-well plates at 37°C in 5% CO_2 for 3 days. AZT was used as a positive control. After post-infection for 3 days, cytopathic effect (CPE) was measured by counting the number of syncytia in each well of 96-well plates under an inverted microscope (10 $\times$) (Nikon ECLIPSE TS100). The inhibitory percentage of syncytia formation was calculated by the percentage of syncytia number in treated sample compared to that in infected control. 50% effective concentration (EC_{50}) was calculated. Therapeutic index (TI) was calculated by the ratio of $\text{CC}_{50}/\text{EC}_{50}$.

Inhibition of HIV-1 p24 antigen level in acute infection

For the compounds with TI value greater than 10, the in vitro inhibitory effect of these compounds on HIV-1 replication was further evaluated by quantification of p24 expression. Briefly, 4×10^5 /ml C8166 cells were infected with HIV-1_{NL4-3} for 2 hours to allow for viral absorption. It was then washed three times with PBS to remove unadsorbed virus. The cells were plated at 4×10^4 cells/well with or without various concentrations of compounds and incubated in a CO_2 incubator at 37°C with for 72 hours. Supernatants were collected and virus was lysed with 0.5% triton X100. HIV-1 p24 was determined with an in-house ELISA assay described previously³¹. The inhibitory percentage of p24 antigen production was calculated by the $\text{OD}_{490/630}$ value of compound-treated culture compared to that in infected control culture and EC_{50} were calculated.

Acknowledgements

This work was supported by the National Basic Research Program of China (Grant No. 2013CB835100), the Key Scientific and Technological Program of China (2014ZX10005-002-006), the National Natural Science Foundation of China (Grant Nos. 31401142, 31401137, 81471620, 81660612), the Instruments Function Deployment Foundation of CAS (2014gk01) and the Applied Basic Research Foundation of Yunnan Province (2014FB181; 2015FB182; P0120150150).

Author contribution

S-X D, Y-T Z and J-F H conceived and designed the research. S-X D, H C, W-X L, Y-C G, J-Q L, J-J Z, Q W, H-J L, B-W C, Y-D G performed data analysis. H C performed the in vitro experiments of anti-HIV activity and cytotoxicity assays. S-X D, H C, W-X L, G-H L, Y-T Z and J-F H wrote or contributed to the writing of the manuscript. All authors reviewed the manuscript.

Conflict of interest

The authors declare that they have no conflict of interest.

References

- 1 Watkins-Hayes, C. Intersectionality and the sociology of HIV/AIDS: Past, present, and future research directions. *Sociology* **40** (2014).
- 2 Tan, X. *et al.* Systematic identification of synergistic drug pairs targeting HIV. *Nat. Biotechnol.* **30**, 1125-1130, doi:10.1038/nbt.2391 (2012).
- 3 Fauci, A. S. HIV and AIDS: 20 years of science. *Nat. Med.* **9**, 839-843, doi:10.1038/nm0703-839 (2003).
- 4 Sliva, K. Latest animal models for anti-HIV drug discovery. *Expert Opin Drug Discov* **10**, 111-123, doi:10.1517/17460441.2015.975201 (2015).
- 5 Kim, J. H., Excler, J. L. & Michael, N. L. Lessons from the RV144 Thai Phase III HIV-1 Vaccine Trial and the Search for Correlates of Protection. *Annual Review of Medicine, Vol 66* **66**, 423-437, doi:10.1146/annurev-med-052912-123749 (2015).
- 6 Haynes, B. F. New approaches to HIV vaccine development. *Curr. Opin. Immunol.* **35**, 39-47, doi:10.1016/j.coi.2015.05.007 (2015).
- 7 Rolland, M. *et al.* Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. *Nature* **490**, 417-420, doi:10.1038/nature11519 (2012).
- 8 Pomerantz, R. J. & Horn, D. L. Twenty years of therapy for HIV-1 infection. *Nat. Med.* **9**, 867-873, doi:10.1038/nm0703-867 (2003).
- 9 Margolis, D. A. & Boffito, M. Long-acting antiviral agents for HIV treatment. *Current Opinion in Hiv and Aids* **10**, 246-252, doi:10.1097/coh.0000000000000169 (2015).
- 10 Zhan, P., Pannecouque, C., De Clercq, E. & Liu, X. Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends. *J. Med. Chem.*, doi:10.1021/acs.jmedchem.5b00497 (2015).
- 11 Chabria, S. B., Gupta, S. & Kozal, M. J. Deep Sequencing of HIV: Clinical and Research Applications. *Annual Review of Genomics and Human Genetics, Vol 15* **15**, 295-325, doi:10.1146/annurev-genom-091212-153406 (2014).
- 12 Kramer, S., De Raedt, L. & Helma, C. in *Proceedings of the seventh ACM SIGKDD international conference on Knowledge discovery and data mining.* 136-143 (ACM).
- 13 Sausville, E. A. & Shoemaker, R. H. Role of the National Cancer Institute in acquired immunodeficiency syndrome-related drug discovery. *J. Natl. Cancer Inst. Monogr.*, 55-57 (2001).
- 14 Gaulton, A. *et al.* ChEMBL: a large-scale bioactivity database for drug discovery. *Nucleic Acids Res* **40**, D1100-1107, doi:10.1093/nar/gkr777 (2012).
- 15 Richman, D. D. HIV chemotherapy. *Nature* **410**, 995-1001, doi:10.1038/35073673 (2001).
- 16 Martin, A. R. & Siliciano, R. F. Progress Toward HIV Eradication: Case Reports, Current Efforts, and the Challenges Associated with Cure. *Annual Review of Medicine, Vol 67* **67**, 215-228,

- doi:10.1146/annurev-med-011514-023043 (2016).
- 17 Dahabieh, M. S., Battivelli, E. & Verdin, E. Understanding HIV Latency: The Road to an HIV Cure. *Annual Review of Medicine*, Vol 66 **66**, 407-421, doi:10.1146/annurev-med-092112-152941 (2015).
- 18 Metzner, K. J. HIV whole genome sequencing now - answering still open questions. *J Clin Microbiol*, doi:10.1128/JCM.03265-15 (2016).
- 19 Tiikkainen, P. & Franke, L. Analysis of commercial and public bioactivity databases. *J. Chem. Inf. Model.* **52**, 319-326, doi:10.1021/ci2003126 (2012).
- 20 Nosengo, N. Can you teach old drugs new tricks? *Nature* **534**, 314-316, doi:10.1038/534314a (2016).
- 21 Li, Y. Y. & Jones, S. J. Drug repositioning for personalized medicine. *Genome Med.* **4**, 27, doi:10.1186/gm326 (2012).
- 22 Jahchan, N. S. *et al.* A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. *Cancer Discov.* **3**, 1364-1377, doi:10.1158/2159-8290.CD-13-0183 (2013).
- 23 Ashburn, T. T. & Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs. *Nat. Rev. Drug Discov.* **3**, 673-683, doi:10.1038/nrd1468 (2004).
- 24 Chopra, S. *et al.* Repurposing FDA-approved drugs to combat drug-resistant *Acinetobacter baumannii*. *J. Antimicrob. Chemother.* **65**, 2598-2601, doi:10.1093/jac/dkq353 (2010).
- 25 Kim, K., Zilbermintz, L. & Martchenko, M. Repurposing FDA approved drugs against the human fungal pathogen, *Candida albicans*. *Ann. Clin. Microbiol. Antimicrob.* **14**, 32, doi:10.1186/s12941-015-0090-4 (2015).
- 26 Kouznetsova, J. *et al.* Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs. *Emerg Microbes Infect* **3**, e84, doi:10.1038/emi.2014.88 (2014).
- 27 Xu, M. *et al.* Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. *Nat. Med.*, doi:10.1038/nm.4184 (2016).
- 28 Clouser, C. L., Patterson, S. E. & Mansky, L. M. Exploiting drug repositioning for discovery of a novel HIV combination therapy. *J. Virol.* **84**, 9301-9309, doi:10.1128/JVI.01006-10 (2010).
- 29 Li, G.-h. & Huang, J.-f. CDRUG: a web server for predicting anticancer activity of chemical compounds. *Bioinformatics* **28**, 3334-3335, doi:10.1093/bioinformatics/bts625 (2012).
- 30 Dai, S.-X. *et al.* In silico identification of anti-cancer compounds and plants from traditional Chinese medicine database. *Sci. Rep.* **6** (2016).
- 31 Liu, G. J., Wang, J. P., Xiao, J. C., Zhao, Z. W. & Zheng, Y. T. Preparation and characterization of three monoclonal antibodies against HIV-1 p24 capsid protein. *Cell. Mol. Immunol.* **4**, 203-208 (2007).
- 32 Reissmann, T., Schally, A. V., Bouchard, P., Riethmiiller, H. & Engel, J. The LHRH antagonist cetrorelix: a review. *Hum. Reprod. Update* **6**, 322-331 (2000).
- 33 Malabarba, A. & Goldstein, B. P. Origin, structure, and activity in vitro and in vivo of dalbavancin. *J. Antimicrob. Chemother.* **55 Suppl 2**, ii15-20, doi:10.1093/jac/dki005 (2005).
- 34 Cortes-Funes, H. & Coronado, C. Role of anthracyclines in the era of targeted therapy. *Cardiovasc. Toxicol.* **7**, 56-60, doi:10.1007/s12012-007-0015-3 (2007).
- 35 Sadanand, S., Suscovich, T. J. & Alter, G. Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design. *Annual Review of Medicine*, Vol 67 **67**, 185-200, doi:10.1146/annurev-med-091014-090749 (2016).
- 36 Beerenwinkel, N. *et al.* Computational methods for the design of effective therapies against drug resistant HIV strains. *Bioinformatics* **21**, 3943-3950, doi:10.1093/bioinformatics/bti654 (2005).
- 37 Bui, Q. C., Nuallain, B. O., Boucher, C. A. & Sloat, P. M. Extracting causal relations on HIV drug

- resistance from literature. *BMC Bioinformatics* **11**, 101, doi:10.1186/1471-2105-11-101 (2010).
- 38 Waheed, A. A. & Tachedjian, G. Why Do We Need New Drug Classes for HIV Treatment and Prevention? *Curr. Top. Med. Chem.* **16**, 1343-1349, doi:10.2174/1568026616999151013124606 (2016).
- 39 Chen, C. Y. TCM Database@Taiwan: the world's largest traditional Chinese medicine database for drug screening in silico. *PLoS One* **6**, e15939, doi:10.1371/journal.pone.0015939 (2011).
- 40 Wishart, D. S. *et al.* HMDB 3.0--The Human Metabolome Database in 2013. *Nucleic Acids Res* **41**, D801-807, doi:10.1093/nar/gks1065 (2013).
- 41 Wishart, D. S. *et al.* HMDB: the Human Metabolome Database. *Nucleic Acids Res* **35**, D521-526, doi:10.1093/nar/gkl923 (2007).
- 42 Grogg, K. L., Miller, R. F. & Dogan, A. HIV infection and lymphoma. *J. Clin. Pathol.* **60**, 1365-1372, doi:10.1136/jcp.2007.051953 (2007).
- 43 Suneja, G. *et al.* Disparities in cancer treatment among patients infected with the human immunodeficiency virus. *Cancer* **122**, 2399-2407, doi:10.1002/cncr.30052 (2016).
- 44 Suneja, G. *et al.* Cancer treatment disparities in HIV-infected individuals in the United States. *J. Clin. Oncol.* **32**, 2344-2350, doi:10.1200/JCO.2013.54.8644 (2014).
- 45 Driscoll, J. S. The preclinical new drug research program of the National Cancer Institute. *Cancer Treat. Rep.* **68**, 63-76 (1984).
- 46 O'Boyle, N. M., Morley, C. & Hutchison, G. R. Pybel: a Python wrapper for the OpenBabel cheminformatics toolkit. *Chem. Cent. J.* **2**, 5, doi:10.1186/1752-153X-2-5 (2008).
- 47 O'Boyle, N. M. *et al.* Open Babel: An open chemical toolbox. *J. Cheminform.* **3**, 33, doi:10.1186/1758-2946-3-33 (2011).
- 48 Delignette-Muller, M. L. & Dutang, C. fitdistrplus: An R Package for Fitting Distributions. *J. Stat. Softw* **64**, 1-34 (2014).
- 49 Orru, G., Pettersson-Yeo, W., Marquand, A. F., Sartori, G. & Mechelli, A. Using Support Vector Machine to identify imaging biomarkers of neurological and psychiatric disease: a critical review. *Neurosci Biobehav Rev* **36**, 1140-1152, doi:10.1016/j.neubiorev.2012.01.004 (2012).
- 50 Burges, C. J. C. A tutorial on Support Vector Machines for pattern recognition. *Data Mining and Knowledge Discovery* **2**, 121-167, doi:10.1023/A:1009715923555 (1998).
- 51 Pedregosa, F. *et al.* Scikit-learn: Machine Learning in Python. *Journal of Machine Learning Research* **12**, 2825-2830 (2011).
- 52 Chang, C. C. & Lin, C. J. LIBSVM: A Library for Support Vector Machines. *Acm Transactions on Intelligent Systems and Technology* **2**, doi:10.1145/1961189.1961199 (2011).
- 53 Breiman, L. Random forests. *Machine Learning* **45**, 5-32, doi:10.1023/A:1010933404324 (2001).
- 54 Pannecouque, C., Daelemans, D. & De Clercq, E. Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later. *Nat. Protoc.* **3**, 427-434, doi:10.1038/nprot.2007.517 (2008).
- 55 Wang, R.-R. *et al.* Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro. *PloS one* **9**, e105617 (2014).

TABLES

Table 1. The cytotoxicity (CC₅₀), anti-HIV-1 activity on HIV-1_{NL4-3} strain (CPE EC₅₀), and therapeutic index (TI) of the tested 28 compounds

Drug name	Drug ID	CC ₅₀ (μM) Mean±SD	EC ₅₀ (μM) Mean±SD	TI
Bivalirudin	DB00006	>200	>200	Inactivity
Carbetocin	DB01282	>200	>200	Inactivity
Cetrorelix	DB00050	>200	15.285±1.024	>12.3^a
Cytarabine	DB00987	101.819±14.844	54.603±14.602	2.9-1.3
Dalbavancin	DB06219	>200	8.694±0.000	>23.0
Daunorubicin	DB00694	0.279±0.085	0.029±0.010	5.0-19.2
Desmopressin	DB00035	>200	>200	Inactivity
Doxorubicin	DB00997	0.191±0.017	0.013±0.001	13.4-17.3
Epirubicin	DB00445	0.125±0.042	0.007±0.003	9.2-41.8
Gatifloxacin	DB01044	116.743±24.863	126.263±16.005	0.6-1.3
Gonadorelin	DB00644	>200	72.417±3.403	>2.6
Idarubicin	DB01177	0.077±0.004	0.004±0.001	18.3-26.7
Levofloxacin	DB01137	>200	17.533±1.456	>10.5
Linaclotide	DB08890	>200	>200	Inactivity
Moxifloxacin	DB00218	102.902±13.248	104.286±13.324	0.8-1.3
Nafarelin	DB00666	>200	>200	Inactivity
Ofloxacin	DB01165	>200	114.097±12.820	>1.6
Pentagastrin	DB00183	>200	93.794±42.202	>1.5
Polymyxin B Sulfate	DB00781	109.157±0.879	15.007±4.186	5.6-10.2
Sofosbuvir	DB08934	>200	>200	Inactivity
Somatostatin	DB09099	>200	>200	Inactivity
sparfloxacin	DB01208	85.112±11.066	31.594±2.029	2.2-3.3
Terlipressin	DB02638	>200	>200	Inactivity
Tolvaptan	DB06212	97.532±16.441	15.816±1.101	4.8-7.7
Triptorelin	DB06825	>200	>200	Inactivity
Valrubicin	DB00385	2.405±0.446	0.082±0.002	23.3-35.6
Vancomycin	DB00512	>200	>200	Inactivity
Verteporfin	DB00460	7.502±3.177	10.235±4.213	0.3-1.8
AZT	DB00006	1031.353±286.058	0.004±0.000	>181324

a. The drugs with TI value more than 10 were highlighted with bold fonts.

Table 2. The anti-HIV-1 activity on HIV-1NL4-3 strain (P24 EC50), and therapeutic index (TI) of the 7 compounds

Drug name	Original indication	EC₅₀(μM) Mean$\pm$SD	TI
Cetrorelix	For assisted reproduction and the inhibition of premature LH surges	1.788 $\pm$ 0.115	>105.1
Dalbavancin	For the treatment of acute bacterial infections caused by the Gram-positive pathogens	1.296 $\pm$ 0.186	>135.1
Daunorubicin	For treatment of leukemia and other neoplasms	0.016 $\pm$ 0.002	17.6-36.4
Doxorubicin	For inhibition of disseminated neoplasma like acute leukemia, Hodgkin's disease and so on	0.012 $\pm$ 0.001	14.5-18.8
Epirubicin	For adjuvant therapy in patients with breast cancer	0.011 $\pm$ 0.004	5.9-23.9
Idarubicin	For treatment of acute myeloid leukemia in adults	0.003 $\pm$ 0.001	18.3-40.0
Valrubicin	For treatment of cancer of the bladder	0.076 $\pm$ 0.032	18.3-64.8
AZT	For treatment of HIV infections	0.005 $\pm$ 0.004	>93161

Figure legends

Figure 1. The flowchart of Anti-HIV-Predictor and drug repositioning. After construction of benchmark dataset, three models (RFW_FP model, SVM model and RF model) were generated to predict anti-HIV activity of chemical compounds by training, parameter selection and 5-fold cross validation. The web server Anti-HIV-Predictor was established by incorporating the three prediction models. The web server was used to screen all FDA approved drugs. Finally, the predicted new anti-HIV compounds were evaluated for anti-HIV activity *in vitro*.

Figure 2. The performance, input and output of Anti-HIV-Predictor. (a) The ROC and AUC for the RFW_FP model (red), SVM model (green) and RF model (blue), respectively. (b) The statistical average results for 10 runs of 5-fold cross validation. The panel indicate the mean and standard deviation values of accuracy, precision, recall and F1 score derived from the RFW_FP model (red), SVM model (green) and RF model (blue), respectively. Vertical lines indicate the standard deviations (SDs). (c) Input interface of Anti-HIV-Predictor. The web server only needs the SMILES of the query compound as input. (d) The output of Anti-HIV-Predictor. The output contains the matched similar compound, the predicting information and the predicting conclusion whether the query compound has anti-HIV activity (see text for details). For example, Anti-HIV-Predictor assigns three ticks for the drug nevirapine and a cross for aspirin.

Figure 3. The results of computational screen of FDA approved drugs using Anti-HIV-Predictor. (a) Three-axis plot of all approved drugs based on the predict scores of the three models (RFW_FP model, SVM model and RF model). Each dot represents a drug. The blue dot means the drug with no anti-HIV activity. The green dot means the drug with anti-HIV activity supported by one or two models. The red dot indicates the drug with anti-HIV activity predicted by all three models. (b) Venn diagram of the screening results. The RFW_FP model, SVM model and RF model predicted 240, 178 and 110 anti-HIV drugs, respectively. The overlap is 67 drugs which are categorized into three groups: approved anti-HIV drugs (25), drugs with anti-HIV activity(7) and drugs with no experimental data (35).

Figure 4. The chemical structures and *in vitro* dose-response curves of the 7 compounds. Each panel contains the structure and curve for one compound. In dose-response curve, the percent inhibition of the compounds on HIV-1 replication in the p24 assay is shown in red circles. And the percent viability in cytotoxicity assays of the compounds on C8166 is shown in filled black squares. With the

increase of concentration of the compounds, the percent inhibition is increased but the percent viability of C8166 is decreased. The percent viability at the concentration equal to EC_{50} is indicated as blue dashed line. Data are mean $\pm$ s.d. (n=6)

anti-HIV activity
data in ChEMBLdb

Benchmark dataset

anti-HIV activity
data in NCI

Training parameter selection

5- fold cross validation

RFW_FP model

SVM model

RF model

Anti-HIV Predictor web server

DRUGBANK
Drug & Drug Target Database

Screening of FDA approved drugs

Candidate Anti-HIV compounds

In vitro anti-HIV activity test

Anti-HIV

New Anti-HIV compounds

c

Anti-HIV Predictor

BSB-KIZ

A web server for predicting the anti-HIV activity of given compounds.

Anti-HIV Predictor web server is user-friendly and free and open to all. The only requirement is the SMILES of the query compound. The SMILES format can be converted from multiple formats (sdf, sd, mol, mol2) by OpenBabel. One or multiple query compounds can be submitted in one request.

Each line should contain a compound's SMILES and a one-word name.

Input example:
CC1=C2N(C(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1 Nevirapine
CCCS(=O)(=O)N(C1=C(F)C(C(=O)C2=CN(C3=NC(C=C(C23)C2=CC=C(C(C(=C2)=O(F)C=C1 Vemurafenib
CC(=O)OC1=CC=CC=C1C(O)=O Aspirin

Output example: [Click to view output example results](#)

How to use

Search and predict

Enter the compounds in the following box:

CC1=C2N(C(=O)C3=C(N=CC=C3)N(C3CC3)C2=NC=C1 Nevirapine
CCCS(=O)(=O)N(C1=C(F)C(C(=O)C2=CN(C3=NC(C=C(C23)C2=CC=C(C(C(=C2)=O(F)C=C1 Vemurafenib
CC(=O)OC1=CC=CC=C1C(O)=O Aspirin

Predict Reset

Input

d

Rank	Query	Match ID	logEC50	TC	RFW_TC	RFW_TC Pvalue	SVM Prob	RF Prob	Anti-HIV
1	Nevirapine	SID_500792	-7.327	1.000	1.000	0.000E+00	0.836	0.695	✓✓✓
2	Vemurafenib	ChEMBL1645560	-5.713	0.473	0.491	4.034E-01	0.881	0.575	✓✓
3	Aspirin	SID_304754	-5.850	0.521	0.527	2.933E-01	0.008	0.001	✗

Output

a

b

25 anti-HIV drugs
7 drugs with anti-HIV activity
35 drugs with no experimental data
(28 drugs tested in this study)